The manifold possible adverse effects from ICI in varied organs must be checked in every patient receiving these medications. AEs tend to occur with higher frequency with combo theray than when these agent are taken in isolation. Anti CTLA-4, anti-CD52, anti-PD1, anti-PDL-1 antibodies (PMID 23714523, 24904570, 25776466). For review of pulmonary and nonpulmonary AEs, and management guidelines see under PMID 26371282, 29442540. Can be fatal (PMID: 29735504). For review see PMID 32158597.

Last update : 17/03/2020
I - Interstitial/parenchymal lung disease
II - Pulmonary edema - Acute lung injury - ARDS
III - Pulmonary/alveolar./airway hemorrhage/bleeding
IV - Airway involvement
V - Pleural and/or pericardial involvement
VI - Pulmonary vasculopathies
VII - Mediastinal involvement
VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
X - Systemic/Distant conditions, syndromes and reactions
XI - Miscellaneous
XII - Cardiovascular involvement / toxicity
XV - Pathology
XVI - Imaging
XVII - Infections & related conditions
XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA